Mylan introduces Divalproex Sodium Capsules for treatment of seizures

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Divalproex Sodium Capsules USP, 125 mg, the generic version of Abbott's Depakote® Sprinkle Capsules, a treatment for certain types of seizures.  

Divalproex Sodium Capsules had U.S. sales of approximately $89 million for the 12 months ending March 31, 2011, according to IMS Health.

Currently, Mylan has 167 ANDAs pending FDA approval representing $100.3 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $25.8 billion in annual brand sales, for the 12 months ending Dec. 31, 2010, according to IMS Health.